Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544851 | 0.93 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2MAPK14 | |
| Oxalic Acid SCHEMBL3544184 | 0.91 | MAPK14 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2RHEB | |
| SCHEMBL3546694 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3MAPK14HTR1A | |
| Oxalic Acid SCHEMBL3548154 | 0.83 | HTR1A (0.47) | SLC6A2SLC6A4SLC6A3RHEBHTR1A | |
| Oxalic Acid SCHEMBL3543674 | 0.83 | HTR1A (0.44) | SLC6A2SLC6A4SLC6A3RHEBMAPK14 | |
| SCHEMBL3546050 | 0.83 | MAPK14 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2MAPK14 | |
| Trifluoroacetic Acid SCHEMBL3543680 | 0.81 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3MAPK14HTR1A | |
| Oxalic Acid SCHEMBL5743276 | 0.81 | SLC6A9 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2MAPK14 | |
| SCHEMBL3542568 | 0.80 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MAPK14HTR1A | |
| SCHEMBL3544011 | 0.79 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732463-B2 | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2010-06-08 | — | — | US | disclosed |
| EP-1626720-B1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-09-03 | — | — | EP | disclosed |
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | H.LUNDBECK A/S (DK) | 2006-05-11 | — | — | US | disclosed |
| EP-1626720-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004087156-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | HTR4, HTR5A, TPH1 | SLC6A4 14/4885SLC6A2 84/4885SLC6A3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.